GlassScriptPhysician profile
Todd R Forrest
NPI 1831187103
$2,897.06
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,461 · 2020: $299 · 2021: $343 · 2022: $269 · 2023: $281 · 2024: $244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $525.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $524.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $450.51 | 2019-2024 | Ozempic, Rybelsus |
| Pfizer INC. | $328.37 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $246.85 | 2019-2024 | Breztri |
| Lilly USA, LLC | $200.14 | 2019-2023 | Jardiance, Emgality |
| Bayer Healthcare Pharmaceuticals INC. | $197.35 | 2022-2024 | |
| Glaxosmithkline, LLC. | $192.85 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $185.50 | 2019-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $176.23 | 2019-2022 | |
| Abbvie INC. | $140.72 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $140.62 | 2019-2020 | |
| Astellas Pharma US INC | $135.70 | 2019-2021 | |
| Amgen INC. | $115.03 | 2019-2024 | Prolia, Evenity |
| Takeda Pharmaceuticals U.S.A., INC. | $65.86 | 2019-2022 | |
| Bausch Health US, LLC | $59.73 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $50.84 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $29.38 | 2019 | |
| Janssen Pharmaceuticals, INC | $27.83 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $26.47 | 2024 | Uzedy |
| Circassia INC. | $17.68 | 2019 | |
| Exact Sciences Corporation | $16.27 | 2024 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $15.36 | 2023 | Rexulti |
| Abbott Laboratories | $14.31 | 2022 | |
| Biogen, INC. | $13.51 | 2021 | |
| Impel Pharmaceuticals INC. | $12.92 | 2022 | |
| Amarin Pharma, INC. | $12.86 | 2020 | |
| Novartis Pharmaceuticals Corporation | $12.36 | 2019 | |
| Mylan Specialty L.P. | $11.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Forrest listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.